Jalaja Potluri, MD of AbbVie Inc. gives an overview of her abstract, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract TPS7069: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia
Advertisement